These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 37079089)
1. Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors. Uslu Y; Kocatepe V; Sezgin DS; Uras C Support Care Cancer; 2023 Apr; 31(5):285. PubMed ID: 37079089 [TBL] [Abstract][Full Text] [Related]
2. A hard pill to swallow: a qualitative study of women's experiences of adjuvant endocrine therapy for breast cancer. Harrow A; Dryden R; McCowan C; Radley A; Parsons M; Thompson AM; Wells M BMJ Open; 2014 Jun; 4(6):e005285. PubMed ID: 24928595 [TBL] [Abstract][Full Text] [Related]
3. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management. Cavazza M; Banks H; Ercolanoni M; Cukaj G; Bianchi G; Capri G; Longo F Breast Cancer Res Treat; 2020 Aug; 183(1):189-199. PubMed ID: 32591986 [TBL] [Abstract][Full Text] [Related]
4. Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence? Ekinci E; Nathoo S; Korattyil T; Vadhariya A; Zaghloul HA; Niravath PA; Abughosh SM; Trivedi MV J Cancer Surviv; 2018 Jun; 12(3):348-356. PubMed ID: 29396760 [TBL] [Abstract][Full Text] [Related]
5. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women. Jahanzeb M Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537 [TBL] [Abstract][Full Text] [Related]
6. Adherence to adjuvant endocrine therapy: is it a factor for ethnic differences in breast cancer outcomes in New Zealand? Seneviratne S; Campbell I; Scott N; Kuper-Hommel M; Kim B; Pillai A; Lawrenson R Breast; 2015 Feb; 24(1):62-7. PubMed ID: 25486877 [TBL] [Abstract][Full Text] [Related]
7. Understanding adjuvant endocrine therapy persistence in breast Cancer survivors. Lambert LK; Balneaves LG; Howard AF; Chia SK; Gotay CC BMC Cancer; 2018 Jul; 18(1):732. PubMed ID: 29996816 [TBL] [Abstract][Full Text] [Related]
8. Adjuvant endocrine therapy for breast cancer. Rao RD; Cobleigh MA Oncology (Williston Park); 2012 Jun; 26(6):541-7, 550, 552 passim. PubMed ID: 22870539 [TBL] [Abstract][Full Text] [Related]
9. Adherence to adjuvant hormonal therapy in localised breast cancer. Davies S; Voutsadakis IA Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13729. PubMed ID: 36207823 [TBL] [Abstract][Full Text] [Related]
10. Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up. Simon R; Latreille J; Matte C; Desjardins P; Bergeron E Can J Surg; 2014 Feb; 57(1):26-32. PubMed ID: 24461223 [TBL] [Abstract][Full Text] [Related]
11. Patient-reported Adherence to Adjuvant Aromatase Inhibitor Therapy Using the Morisky Medication Adherence Scale: An Evaluation of Predictors. Kesmodel SB; Goloubeva OG; Rosenblatt PY; Heiss B; Bellavance EC; Chumsri S; Bao T; Thompson J; Nightingale G; Tait NS; Nichols EM; Feigenberg SJ; Tkaczuk KH Am J Clin Oncol; 2018 May; 41(5):508-512. PubMed ID: 27322700 [TBL] [Abstract][Full Text] [Related]
12. Identifying adherence barriers to oral endocrine therapy among breast cancer survivors. Paranjpe R; John G; Trivedi M; Abughosh S Breast Cancer Res Treat; 2019 Apr; 174(2):297-305. PubMed ID: 30523459 [TBL] [Abstract][Full Text] [Related]
13. Informing women with breast cancer about endocrine therapy: effects on knowledge and adherence. Heisig SR; Shedden-Mora MC; von Blanckenburg P; Schuricht F; Rief W; Albert US; Nestoriuc Y Psychooncology; 2015 Feb; 24(2):130-7. PubMed ID: 24953538 [TBL] [Abstract][Full Text] [Related]
14. Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study. Wigertz A; Ahlgren J; Holmqvist M; Fornander T; Adolfsson J; Lindman H; Bergkvist L; Lambe M Breast Cancer Res Treat; 2012 May; 133(1):367-73. PubMed ID: 22286315 [TBL] [Abstract][Full Text] [Related]
15. Adherence to long-term adjuvant hormonal therapy for breast cancer. Gotay C; Dunn J Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):709-15. PubMed ID: 22098287 [TBL] [Abstract][Full Text] [Related]
16. Behavioral Interventions to Enhance Adherence to Hormone Therapy in Breast Cancer Survivors: A Systematic Literature Review. Hurtado-de-Mendoza A; Cabling ML; Lobo T; Dash C; Sheppard VB Clin Breast Cancer; 2016 Aug; 16(4):247-255.e3. PubMed ID: 27133733 [TBL] [Abstract][Full Text] [Related]
17. Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer. Ejlertsen B; Jensen MB; Mouridsen HT; Acta Oncol; 2014 Feb; 53(2):174-85. PubMed ID: 24219541 [TBL] [Abstract][Full Text] [Related]
18. Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients. He W; Smedby KE; Fang F; Olsson H; Margolin S; Hall P; Czene K J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28423398 [TBL] [Abstract][Full Text] [Related]
19. Adherence to adjuvant endocrine therapy in postmenopausal breast cancer patients: A 5-year prospective study. Hagen KB; Aas T; Kvaløy JT; Søiland H; Lind R Breast; 2019 Apr; 44():52-58. PubMed ID: 30641300 [TBL] [Abstract][Full Text] [Related]
20. Adherence to Adjuvant Endocrine Therapy in Women With Breast Cancer: A Prospective Observational Study in Japanese Women. Kuba S; Maeda S; Matsumoto M; Yamanouchi K; Yano H; Morita M; Sakimura C; Hatachi T; Tokai Y; Takatsuki M; Fujioka H; Hayashida N; Nagayasu T; Eguchi S Clin Breast Cancer; 2018 Apr; 18(2):150-156. PubMed ID: 29290564 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]